Read news on evaluating genentech with our app.
Read more in the app
Alliance Foundation Trials and Natera announce AFT-70 Navigate: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER+/HER2− Br